Loading
Prostate Cancer Treatment and Research / Extracellular Vesicles in Disease · Journal article
Cells · August 13, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes existing knowledge on how cellular senescence, inflammaging, and immune dysfunction in aging may contribute to prostate cancer initiation, progression, and treatment resistance. The work proposes mechanistic frameworks and therapeutic targets but reports no original empirical evidence, clinical trial data, or quantified clinical outcomes to support causal relationships or efficacy claims.
Journal article. Older men with prostate cancer (conceptual review; no cohort studied).
Aging reshapes the prostate microenvironment through cellular senescence, chronic low-grade inflammation, immune dysfunction, stromal remodeling, metabolic stress, and impaired tissue repair. Senescent epithelial and stromal cells release cytokines, chemokines, growth factors, matrix-remodeling enzymes, and extracellular vesicles via the senescence-associated secretory phenotype (SASP). Immune aging alters T-cell subsets, myeloid cells, macrophages, and anti-tumor surveillance, with potential impact on Th17/Treg imbalance and IL-17/IL-23 signaling.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies putative mechanisms that may explain elevated prostate cancer risk and progression in aging. Clinicians should view the proposed therapeutic targets (cytokine modulation, senescence-directed therapy, metabolic intervention) as speculative until validated in preclinical or clinical trials.
A mechanistic review proposing conceptual frameworks linking cellular senescence and inflammaging to prostate cancer, without original empirical data or clinical trials to support causal claims or therapeutic efficacy.
This review identifies putative mechanisms that may explain elevated prostate cancer risk and progression in aging. Clinicians should view the proposed therapeutic targets (cytokine modulation, senescence-directed therapy, metabolic intervention) as speculative until validated in preclinical or clinical trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Prostate cancer is common in older men, yet mechanisms linking aging to tumor progression remain incompletely defined. Beyond genetic alterations, aging reshapes the prostate microenvironment through cellular senescence, chronic low-grade inflammation, immune dysfunction, stromal remodeling, metabolic stress, and impaired tissue repair, collectively promoting inflammaging. This persistent inflammatory state may create a permissive niche for tumor initiation, progression, immune evasion, and treatment resistance. Senescent epithelial and stromal cells release cytokines, chemokines, growth factors, matrix-remodeling enzymes, and extracellular vesicles through the senescence-associated secretory phenotype (SASP). In parallel, immune aging alters T-cell subsets, myeloid cells, macrophages, and anti-tumor surveillance. This review summarizes how SASP programs, Th17/Treg imbalance, IL-17/IL-23 signaling, myeloid remodeling, stromal aging, metabolic stress, and immune–stromal–epithelial crosstalk shape prostate cancer biology. We further discuss therapeutic implications, including cytokine modulation, senescence-directed therapy, metabolic intervention, and biomarker-guided strategies. This review highlights key knowledge gaps and proposes a framework for age-aware prostate cancer research, biomarker development, and therapeutic strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.